Alpha 2.0
Login Register
» Authors » Faatima Laher Omar

Faatima Laher Omar

Explore the profile of Faatima Laher Omar including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 18
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Biomedical Engineering
Top 10 Co-Authors
M Juliana McElrath
Erica Andersen-Nissen
Lawrence Corey
Kelly E Seaton
Zoe Moodie
Georgia D Tomaras
Carlos A DiazGranados
James G Kublin
Fatima Laher
One Dintwe
Published In
J Infect Dis
EBioMedicine
J Leukoc Biol
PLoS Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, et al.
EBioMedicine . 2024 Sep; 108:105320. PMID: 39236556
Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based...
2.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial
Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe O, Laher Omar F, Kee J, et al.
PLoS Med . 2024 Mar; 21(3):e1004360. PMID: 38502656
Background: Adjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the...
3.
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120
Chirenje Z, Laher F, Dintwe O, Muyoyeta M, deCamp A, He Z, et al.
J Infect Dis . 2023 Oct; 230(2):e405-e415. PMID: 37795976
Background: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent...
4.
Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine-induced T-cell responses
Dintwe O, De Rosa S, Huang Y, Flach B, Manso B, Carter D, et al.
J Leukoc Biol . 2022 Jul; 112(5):1167-1181. PMID: 35866359
The HIV Vaccine Trials Network (HVTN) conducts clinical trials on 4 continents in pursuit of a safe and effective HIV vaccine. Cellular immune responses to vaccination that define vaccine immunogenicity...
5.
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, et al.
J Infect Dis . 2022 Jun; 226(2):246-257. PMID: 35758878
Background: The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates...